Company Event • 04 Mar 2026 21:00 • Upcoming
Add To Calendar
Company Event • 26 Aug 2026 20:00 • Upcoming
Add To Calendar
Company Event • 27 Aug 2025 21:00 • Latest
Company Event • 02 Jun 2025 21:00
Company Event • 27 Feb 2025 17:00
Search or
𝛼SK
𝛼SKENTITY
Faron Pharmaceuticals Oy (FARN LN)
Faron Pharmaceuticals Oy (FARN LN)
2
Analysis
Health Care • Finland
Faron Pharmaceuticals Oy operates as a drug discovery and development company in Finland. It has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy, and vascular damage. The company?s lead product candidate includes Traumakine, a recombinant human IFN beta-1a, which is Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It is also developing Clevegen, a pre-clinical immunotherapy candidate, designed to prevent tumor growth and metastasis which targets the tumor immune suppressor molecule; Farbetic, an AOC3 inhibitor, for use in the prevention of vascular deformations in various disease conditions, such as diabetes; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. The company was founded in 2003 and is based in Turku, Finland. Faron Pharmaceuticals Oy is a subsidiary of Faron Ventures Oy.
morex